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SYNTHESIS, CHARACTERIZATION AND CYTOTOXICITY OF BIS(BIPYRIDINE) 
RUTHENIUM(II) COMPLEXES WITH PICOLINIC ACID DERIVATIVES 
SUMMARY 
 
 
SUMMARY 
 
 Bis(bipyridine)ruthenium(II) complexes (1-5) of general formula [Ru(L)(bpy)2]PF6, 
where bpy = 2,2′-bipyridine; HL = 3-methylpyridine-2-carboxylic acid (HL1), 6-
methylpyridine-2-carboxylic acid (HL2), 5-bromopyridine-2-carboxylic acid (HL3) 6-
bromopyridine-2-carboxylic acid (HL4) and pyridine-2,4-dicarboxylic acid (HL5) were 
synthesized and fully characterized. For compounds 3, 4 and 5 single-crystal X-ray diffraction 
analyses were also performed. The electrochemical character of the complexes was investigated 
by cyclic voltammetry revealing Ru(II)/Ru(III) electron transfer in the positive range of 
potentials. On the opposite potential side, multiple partially reversible peaks are dominant 
representing subsequent reductions of the bulky bipyridyl moiety. Cytotoxicity studies by MTT 
assay for 72 h of drug action, revealed that complexes 2-4 exhibited moderate activity in cervical 
human tumor cells (HeLa), with IC50 values (μM): 132.3 ± 5.0 (2), 184.0 ±16.2 (3), 147.7 ± 8.0 
(4). Complex 2 exhibited activity in colon cancer LS-174 cells (180.9 ± 10.1), while complexes 
were devoid of activity in lung cancer A549 and non-tumor MRC-5 cells, in the range of 
concentrations up to 200 μM for complexes 1-4 and up to 300 μM for complex 5. Moderate 
cytotoxicity of complexes 1-5 may be due to faster ligand dissociation kinetics, and greater off-
target reactivity, when once in solution. Still, minor variations in the structure of the co-ligand 
resulted in variations of IC50 values obtained in HeLa cells. Combinational studies of the most 
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active complex 2, with pharmacological modulators of cell redox status, L-buthionine-
sulfoximine (L-BSO) or N-acetyl-L-cysteine (NAC), showed that when L-BSO potentiated, 
complex 2 induced a sub-G1 peak of the cell cycle, in the HeLa cell line. Also, the obtained 
results for the same complex indicated that there is no influence on cell survival, at the same 
time. In addition to the cytotoxicity studies, UV-vis and cyclic voltammetry were performed in 
order to investigate the binding mode of the complex 2 to DNA. The results obtained using 
mutually complement methods suggested an intercalation mode of the complex-DNA 
interaction. 
 
 
 
 
Keywords: bis(Bipyridine)ruthenium(II) complexes, Crystal structure, Redox properties, 
Cytotoxicity, Picolinic ligands. 
Area of science: Chemistry 
Sub-area of science: General and inorganic chemistry 
UDC number: 546 
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SINTEZA, KARAKTERIZACIJA I CITOTOKSIČNOST BIS(BIPIRIDIN) 
RUTENIJUM(II) KOMPLEKSA SA DERIVATIMA PIKOLINSKE KISELINE 
 
 
REZIME 
 
 
 Bis(bipiridin)rutenijum(II) kompleksi (1-5) opšte formule [Ru(L)(bpy)2]PF6, gde je bpy = 
2,2′-bipiridin; HL = 3-metilpiridin-2-karboksilna kiselina (HL1), 6-metilpiridin-2-karboksilna 
kiselina (HL2), 5-bromopiridin-2-karboksilna kiselina (HL3) 6-brompiridin-2-karboksilna 
kiselina (HL4) i piridin-2,4-dikarboksilna kiselina (HL5) su sintetisani i potpuno okarakterisani. 
Za jedinjenja 3, 4 and 5 urađena je difrakcionom analizom X-zraka na monokristalu. 
Elektrohemijski karakter kompleksa je ispitivan cikličnom voltametrijom, ukazujući na 
Ru(II)/Ru(III) transfer elektrona, u opsegu pozitivnih potencijala. Sa druge strane, u opsegu 
negativnih potencijala, zapaţeni su višestruki reverzibilni pikovi koji predstavljaju sukcesivne 
redukcije bipiridinskog dela. Citotoksično delovanje ovih jedinjenja ispitano je primenom MTT 
testa nakon 72 h delovanja kompleksa. Dobijeni rezultati ukazuju da kompleksi 2-4 ispoljavaju 
umerenu aktivnost prema humanoj ćelijskoj liniji grlića materice (HeLa), sa IC50 vrednostima 
(μM): 132.3 ± 5.0 (2), 184.0 ±16.2 (3), 147.7 ± 8.0 (4). Kompleks 2 ispoljio je aktivnost prema 
ćelijama kancera debelog creva LS-174 cells (180.9 ± 10.1), dok je aktivnost izostala prema 
tumorskim ćelijama pluća A549 i netumorskim ćelijskim linijama MRC-5, u opsegu 
koncentracija do 200 μM za komplekse 1-4 i do 300 μM za kompleks 5. Umerena citotoksična 
aktivnost kompleksa 1-5 je najverovatnije uslovljena brzom disocijacijom liganada pri samom 
rastvaranju kompleksa pri fiziološkim uslovima. Male varijacije u strukturi koliganda rezultovale 
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su u promeni IC50 vrednosti na HeLa ćelijskoj liniji. Kombinovane studije najaktivnijeg 
kompleksa 2 sa farmakološkim modulatorima ćelijskog redoks statusa, L-
butioninsulfoksaminom (L-BSO) ili N-acetil-L-cisteionom (NAC), pokazale su da u slučaju L-
BSO, kompleks 2 izaziva sub-G1 pik u ćelijskom ciklusu, na HeLa linijama. Istovremeno, 
dobijeni rezultati sa istim kompleksom su pokazali da nema uticaja na ćelijsko preţivljavanje. 
Pored ispitivanja citotoksičnosti, UV-vis spektroskopijom i cikličnom voltametrijom ispitivano 
je vezivanje kompleksa 2 za DNK. Dobijeni su rezultati koji ukazuju na interkalaciju kompleksa 
sa DNK. 
 
 
 
 
Ključne reči: bis(bipiridin)rutenijum(II) kompleksi, kristalna struktura, redoks svojstva, 
citotoksičnost, pikolinato ligandi. 
Naučna oblast: Hemija 
Uţa naučna oblast: Opšta i neorganska hemija 
UDK broj: 546 
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1. INTRODUCTION 
 
 
Precious metals have been used for medicinal purposes for at least 3500 years, when records 
show that gold was included in a variety of medicines in Arabia and China [1]. In general, metal 
based drugs have utilized their pathway and future development in the field of inorganic 
medicine chemistry [2-4]. Since the Rosenberg’s discovery of cisplatin’s cytotoxicity [5,6], a 
large number of scientists have been inspired to design unique compounds that would eventually 
resolve well known limitations of commercial drugs (resistance and side effects) [7]. Among the 
different transition metal centers that have been exhaustively studied for therapeutic applications, 
Ru is particularly suitable for the design of metal-based drugs [8]. In the chemical context, Ru 
forms coordination bonds that are substitutionally inert and consequently Ru complexes are less 
susceptible to ligand substitution in biological conditions. So far, two Ru complexes (NAMI-A 
and KP1019) have undergone clinical trials [9,10].  
The selection of the ligand system certainly represents the promising base in the design of active 
metal complex. The ligands moiety can be responsible for redox activity as well as for anticancer 
activity. It can be also improve the solubility of the complex, reduce toxicity and enhance 
specificity. Some studies showed how low antitumor activity of the ligand can be improved by 
coordinating to the metal center [11]. From a strictly chemical point of view, metal-ligand 
synergism intruded most probably as the main spot in designing the perfect drug structure. 
Moreover, the ligand carrier may originate from a structure that has a rather specific role in some 
biological system. In that sense, some authors emphasize the significance of picolinic acid (2-
pyridinecarboxylic acid) [12-14]. This six-membered ring molecule is found in mother's milk 
and has a direct impact on mineral uptake in humans [15]. Beside its wide variety of 
physiological properties, picolinic acid is also an industrially significant compound. It is used as 
an active substance in a great number of dietary supplements [16,17]. Picolinic acid and its 
derivatives are present in the literature as multidentate ligands whose coordination modes rely on 
two different ligator atoms [18,19].  
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As modern cancer therapy imposes even more rigid criteria for the final clinical use, the whole 
metal drug concept is subject to significant change. Thus every extensive study includes the 
synthetic route followed by structural and electrochemical characterization, in vitro and DNA 
targeting tests as well as examination of protein inhibition. 
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2. GENERAL PART 
 
2.1. Platinum complexes in treatment of cancer 
 
cis-Diamminedichloridoplatinum(II) (cisplatin) was first described by Peyrone in 1845 
[1]. Its activity against cancer was revealed in 1964, when Rosenberg realized that the platinum 
electrodes in the NH4Cl solution used in one of his experiments affected bacterial growth [2,3]. 
The main species responsible for that was found to be cis-[Pt(NH3)2Cl2], which was formed 
slowly by reaction of the electrodes with solution of NH4Cl. The drug entered clinical trials in 
1971 and by the end of 1987 it was already the most widely used as anticancer drug in medicine 
[4] with anticancer activity against certain types of tumors. Unfortunately, some tumors avoid 
the action of cisplatin, demonstrating intrinsic or acquired resistance. Also, administration of 
cisplatin causes severe side-effects, namely neurotoxicity, ototoxicity, nausea, vomiting, bone 
marrow dysfunction and nephrotoxicity. In the blood, the high physiological chloride 
concentration (ca. 100 mM) ensures that the complex remains neutral until it enters the cell. This 
passage through membrane was thought to occur mainly by passive diffusion, but also active 
transport by the copper transporter Ctr1p could not be excluded [5]. Once in the cytosol, 
hydrolysis occurs due to the lower chloride concentration (ca. 4 mM). The mechanism of action 
includes interaction with DNA which is considered as an ultimate target of cisplatin [6]. The 
DNA coordination sites of cisplatin after hydrolysis are, in order of preference, the N7 atom of 
guanine, the N7 atom of adenine, the N1 adenine, and N3 of cytosine. Bifunctional binding 
results in chelation and subsequent formation of various adducts in DNA. Intrastrand 1,2-d(GpG) 
cross-links are the most abundant Pt-DNA adducts (60-65% of the platinum bound to DNA is in 
that form) [7], followed by intrastrand d(ApG) cross-links (around 20% of the bound platinum). 
Only about 1.5% of the cisplatin was found to be involved in interstrand adducts; some minor 
DNA-protein cross-links were also can be formed (Figure 1) [8-10].  
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Figure 1. Schematic view of a double-stranded DNA, depicting some of the most commonly occurring Pt-DNA 
adducts. 
This drug has guided the search for new chemical entities to overcome limitations and many 
other complexes of platinum and other transition metals, besides platinum, were tested to this 
aim leading to some thousands molecules with varying degrees of success [11-15]. 
Research has been focused on several fronts. For the design of improved pharmaceuticals it is 
crucial to understand the transport of the drug in the body, cellular uptake, and its fate inside the 
cell. The development of synthetic methods rapidly increased the number of compounds that 
were screened for anticancer activity. Also, since cisplatin is definitely effective against certain 
tumours, studies were also included the avoidance of undesired side effects, with the retention of 
the therapeutic value of the drug. 
Thousands of platinum compounds have been synthesized in an attempt to overcome the 
problems of cisplatin. The observation of the first platinum complex and its efficacies as 
antitumor agent led to what was called the “structure-activity relationships” (SAR’s). This was a 
list of structural characteristics that a platinum complex requires in order to show an antitumor 
activity and the most of the new compounds were designed according to these rules. The most 
successful of the second-generation platinum compounds is cis-diammine-1,1-cyclobutane-
dicarboxylatoplatinum(II), known as carboplatin (Figure 2). It was introduced in clinics in 1986 
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and its activity is equivalent to cisplatin in the treatment of ovarian cancers, however in the 
treatment of testicular, head and neck cancers cisplatin is superior [16,17]. Also, carboplatin has 
less severe side effects than cisplatin, but it is cross-resistant with it. Two other second- and 
third-generation compounds have been approved for clinical use. cis-
Diammine(glycolato)platinum(II) (nedaplatin) [18] was approved in 1995 by the Health and 
Welfare Ministry in Japan [19] and various studies of combined therapies of the platinum 
complex with other drugs are undergoing clinical trials for the treatment of urothelial, uterine, 
lung, esophageal or testicular cancer, amongst others [20-26]. (1R,2R-
Diaminocyclohexane)oxalatoplatinum(II) (oxaliplatin) [27] was approved in France and in a few 
other European countries mainly for the treatment of metastatic colorectal cancer. 
 
 
Figure 2. Molecular structure of a few selected platinum drugs: cisplatin, carboplatin, nedaplatin and oxaliplatin. 
 
Since it has become evident that mere analogues of cisplatin or carboplatin would probably not 
offer any substantial clinical advantages over the existing drugs, as complexes of this kind can be 
expected to have similar biological consequences to cisplatin, some platinum complexes were 
synthesized despite contradicted the SAR’s. 
 
2.2. Other platinum complexes  
 
The design of platinum(IV) complexes yielded a new concept in platinum anticancer therapy. 
Additional axial preferably lipophilic ligands would facilitate intestinal absorption of the drug, 
making oral administration possible [28]. Also, they would act as pro-drugs, which get reduced 
to platinum(II) by intracellular glutathione, ascorbic acid or other reducing agents. The 
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platinum(II) would bind subsequently to DNA and exert the desired action [29]. The most 
successful Pt(IV) complex is bis(acetato)amminedichlorido(cyclohexylamine)platinum(IV) 
(Figure 3), also known as satraplatin or JM216. Satraplatin also shows in vivo oral antitumor 
activity against a variety of murine and human subcutaneous tumor models, comparable to the 
activity of cisplatin. In addition, it has a relatively mild toxicity profile, being myelosuppression 
instead of nephrotoxicity the dose- limiting factor [30]. 
One approach covers so called sterically hindered cis-platinum(II) complexes that contain 
sterically crowded non-leaving groups. For instance, cis-amminedichlorido(2-
methylpyridine)platinum(II) (ZD0473 or AMD473) was selected for clinical trials [31]. Phase-II 
clinical trials carried out with lung and metastatic breast cancer patients showed a good 
tolerability of the drug, but no greater efficacy over existing agents in platinum-resistant patients 
[32]. Studies are ongoing of combined therapy with liposomal doxorubicin or paclitaxel [33].  
 
 
Figure 3. Molecular structure of the anticancer platinum complexes satraplatin or JM216 (a Pt (IV) complex, on the 
left) and ZD0473 (a Pt (II) complex, on the right). 
In the search for complexes that followed a different mechanism to cisplatin the first SAR-rule, 
that complex must be of cis geometry, was revised. The trans-Pt(II) complexes that have been 
synthesized so far can be divided into several groups that respond to the general formula trans-
[PtCl2(L)(L’)]. The pioneers were Farrell and his group, with complexes where L = a pyridine as 
ligand and L´= an ammine, a sulfoxide or a pyridine group [34-38]. Following his example, other 
groups synthesized more trans-Pt(II) complexes, finding in some cases very good anticancer 
activities. Navarro-Ranninger and her group focused on complexes with L = L’ = branched 
aliphatic amines [39,40]. Gibson and others reported that the replacement of one of transplatin´s 
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ammine ligands by a heterocyclic ligand, such as piperidine, piperazine or 4-picoline, resulted in 
a radical enhancement of the cytotoxicity [41,42]. Finally the group of Natile and Coluccia 
synthesized complexes where L = an iminoether ligand and L´ = an amine or one more 
iminoether ligands [43,44] (Figure 4). All these groups have reported that the cytotoxic ability of 
the above described trans-platinum complexes with bulky non-leaving groups is in some cases 
superior to that shown by cisplatin, and often better than the cytotoxicity of their respective cis- 
analogues. These trans-complexes are characterized by a spectrum of activity different from 
cisplatin and they often overcome resistance. 
 
 
Figure 4. Examples of trans-platinum complexes 
 
2.3. An alternative to platinum therapy: Ruthenium complexes 
 
To overcome the limitations of platinum complexes many compounds based on ruthenium have 
been developed and tested against cancer cell lines [45]. These compounds tend to cause fewer 
and less severe side effects compared to platinum drugs. Chemistry of ruthenium is well suited 
towards potential pharmacological applications. Synthetic chemistry of ruthenium is developed; 
ruthenium tends to form octahedral complexes, which allows two additional ligands comparing 
with square planar platinum(II) complexes; coordination to different ligator atoms, varying in 
hardness and electronegativity; and finally availability of different oxidation states, with +2 and 
+3 being the most interesting. The latest is thought to be reason for less toxicity of ruthenium 
compounds with hypothesis of activation by reduction. This theory is based on the observation 
that ruthenium(III) complexes are more inert than ruthenium(II) and the cancer cells are hypoxic 
in the more chemical reducing environment, than healthy cells. These two factors mean that 
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compounds of ruthenium can be administered in the (relatively inert) +3 oxidation state, causing 
minimal damage to healthy cells, but being reduced to the (active) +2 oxidation state in cancer 
cells [46-50]. 
In general, two approaches are commonly used for the design of new anticancer compounds. The 
first one, trial-and-error approach is based on synthesis as many compounds as possible that are 
similar to a complex of known activity, with the aim to solve its drawbacks. These new 
compounds are then tested, first in vitro followed by in vivo. The second approach consists of 
thorough studies of the properties of some particular complex, that include its chemical, physical, 
pharmacological properties, the uptake of the drug, its biodistribution and its detoxifying 
processes with the aim to reach desired activity and overcome drawbacks. This demands 
multidisciplinary approach in which collaboration from different scientific fields is necessary.  
The first generation of ruthenium compounds synthesized for anticancer purposes were 
structurally similar to cisplatin: several ammine and chlorido ligands were coordinated to Ru(II) 
and Ru(III) to form complexes with general formula [Ru(NH3)6-xClx]
n+
. Those complexes in 
which the oxidation state of the ruthenium ion was +2 were targeted DNA in an analogous way 
to cisplatin as the experiments with [Ru(NH3)5Cl]
+
and [Ru(NH3)5(H2O)]
2+
confirmed (Figure 5). 
However, cytotoxicity tests showed poor activity. Interestingly, both cis-[Ru(NH3)4Cl2]
+
 and 
especially fac-[Ru(NH3)3Cl3] displayed a comparable antitumor activity to that of cisplatin in a 
few selected cell lines [51,52]. It has been hypothesized that these complexes, once inside the 
cell, are reduced to less inert Ru(II) species, which bind to DNA after hydrolysis [53]. The 
trichloride complex, being the most promising of all these compounds, was discarded for further 
investigation due to its poor water solubility. 
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Figure 5. Examples of ammine-chlorido ruthenium complexes, [Ru(NH3)5Cl]
+
 , cis-[Ru(NH3)4Cl2]
+
 and fac-
[Ru(NH3)3Cl3]. 
The substitution of the ammine ligands by DMSO molecules yields compounds with improved 
solubility. Both cis- and trans-[Ru(II)Cl2(DMSO)4] (Figure 6) were shown to be able to 
coordinate to guanine residues of DNA via the N7 position with the trans complex being more 
active due to differences in kinetics. In addition, the trans isomer also seemed to be able to 
overcome cisplatin resistance, and along with good antimetastatic activity represented an 
interesting alternative to cisplatin [54]. Afterwards, the series of dimethyl sulfoxide-ruthenium 
complexes were designed, inspired on that promising compound. Noteworthy are the compounds 
Na{trans-[Ru(III)Cl4(DMSO)(Him)]}, (Him = imidazole), nicknamed NAMI, and the more 
stable [H2Im][trans-Ru(III)Cl4(DMSO)(Him)], also known as NAMI-A (Figure 6). NAMI-A is 
the first ruthenium complex to have ever reached clinical testing for anticancer activity. 
Nowadays, when surgical removal of primary cancers is efficient and successful, a complex such 
as NAMI-A, which presents an antimetastatic activity in a broad range of tumours including lung 
metastasis, is becoming of utmost interest [55-57]. 
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Figure 6. Examples of dimethylsulfoxide complexes. From left to right, trans-[Ru(II)(DMSO)4Cl2], Na{trans-
[Ru(III)Cl4(DMSO)(Him)]} (NAMI) and [H2Im]{trans-[Ru(III)Cl4(DMSO)(Him)]} (NAMI-A). 
The second complex in clinical evaluation comes from Keppler’s group [58]. In that research 
group were prepared the series of anionic ruthenium(III) complexes with monodentate 
heterocyclic nitrogen donor ligands, the most successful have the formula trans-[RuCl4(L)2]
-
, 
where L is imidazole (KP418) or indazole (KP1019 and KP1339), and the counterion (LH)
 +
 or 
Na
+
 (Figure 7). KP1019 and KP1339 were reported effective in inhibiting platinum-resistant 
colorectal carcinomas in rats [59]. 
 
 
Figure 7. Molecular structure of the ruthenium(III) complexes imidazolium 
[tetrachloridobis(imidazole)ruthenate(III)] (KP418), indazolium trans-[tetrachloridobis(indazole)ruthenate(III)] 
(KP1019) and sodium trans-[tetrachloridobis(indazole)ruthenate(III)] (KP1339). 
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The mechanism of action of these complexes is thought to differ considerably from that of 
cisplatin. The involvement of the “activation-by-reduction” process and the transferring 
mediated transport into the cells seem to play a very important role in the efficiency of the 
“Keppler-type” complexes [60], as in the case of NAMI-A. 
Organoruthenium complexes have received considerable attention in recent years, since a large 
number of applications in supramolecular [61] and medicinal chemistry have been developed 
with excellent or promising results. 
Organoruthenium complexes are appealing in drug design because, like platinum complexes, 
they exhibit slow rates of ligands dissociation in biological systems, allowing for a more 
controlled release of active drug since that slow down deactivation of the drug before it reaches 
target and decrease potential side effects.  
In particular, ruthenium arene complexes are substitutionally inert under biological systems [62] 
and service as an excellent platform for drug development in cancer therapies [63]. Ruthenium-
arene-chloride dimeric complexes [(ɳ6-arene)RuCl2)]2 are good starting materials that could 
generate variety of ruthenium derivatives to be used as anticancer drugs [64-66]. The complex 
[Ru(ɳ6-p-cymene)Cl2(pta)] called RAPTA-C (Figure 8) has been shown to have moderate 
anticancer activity in various cell lines and an excellent activity against solid metastases and has 
been pointed out to be the best anticancer complex [67]. 
 
Figure 8. Molecular structure of RAPTA, RAPTA-T and RAPTA-C 
 
Despite in depth in vitro, in vivo and theoretical studies on the behavior of the potential RAPTA 
anticancer drugs the mechanism of action of these complexes is not well known, but poor 
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correlation between the binding of RAPTA complexes to DNA and their cytotoxicity suggested 
that these potential anticancer drugs act through a mechanism different from the classical 
platinum anticancer drugs [68]. Organoruthenium systems developed by Sadler et al. (Figure 9) 
have not been shown to be much cytotoxic but they transport into cell intact better than cisplatin 
due to the presence of the lipophilic arene. This group also pointed out chloride dissociation as 
the limiting factor to the effectiveness of organoruthenium compounds in causing cell death 
[69,70]. 
 
 
Figure 9. Molecular structure of [Ru(arene)enCl]
+ 
complexes 
Finally, the complexes that are notable to mention in the light of this dissertation are the 
ruthenium complexes with pyridine, bipyridine or terpyridine ligands [71]. Ruthenium(II) tris 
bipyridine complex has been thoroughly studied during the last 30 years as a result of their 
remarkable chemical stability and photophysical properties. These complexes found wide 
applications in different areas, from solar energy to molecular wiresand switches mechanics as 
well as potential therapeutic agents [72]. 
Among those ruthenium complexes, compounds bearing a 2,2’-bipyridine moiety are also well 
recognized, not only as potential drugs but also as highly diverse photochemical and redox 
systems [73,74]. Thus, the unique combination of (electro)chemical properties makes them very 
attractive in terms of different potential applications (e.g. chemotherapy, catalysis) [75,76]. 
Several ruthenium polypyridyl complexes were synthesized, and theirs in vitro antitumour 
activity as well as DNA binding was studied [77,78].  
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Particularly is interesting application of such types of complexes as intercalation agents. 
Intercalating molecule have been subjects of many studies because intercalation distorts the 
helical shape of DNA. To date, many [RuL(bpy)2]
2+
 and [RuL(phen)2]
2+
 complexes have been 
described, where L is an aromatic bidentate ligand, which have been proven to interact with 
DNA via intercalation [79-84]. 
Among the many complexes studied, the ruthenium(II)bis(bipyridine) complex with 
dipyridophenazine, [Ru(bpy)2(dppz)]
2+
 (Figure 10), was demonstrated to have extraordinary 
properties, notably the ability to act as a “light switch” when bound to DNA [85]. Although such 
results for [Ru(bpy)2(dppz)]
2+
 appeared nearly two decades ago, this complex remains the 
subject of recent investigations which aim to clarify conditions under which it demonstrates 
multiple binding modes [86].  
 
 
Figure 10. Molecular structure of [Ru(bpy)2(dppz)]
2+
 
 
2.4. Ligands and corresponding complexes: Structures and biological features 
 
Pyridinedicarboxylic acids are well known for their biological features. 2,4-Pyridinedicarboxylic 
acid demonstrated imunosupressive and fibrosupressive characteristic and along with 2,5- and 
2,6-pyridinedicarboxylic acid acts as inhibition or activation agents for some metaloenzymes 
[87,88]. Usually, they coordinate to metals in a bidentate manner, via pyridine nitrogen and 
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carboxylate oxygen, leaving another carboxylate group uncoordinated. It is important to mention, 
ruthenium-cymene complexes with this type of ligands, have been recently reported [89-92].  
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3. EXPERIMENTAL PART 
 
3.1. Materials and methods for the synthesis and characterization 
 
 All experiments were performed under atmospheric conditions with commercially 
available chemicals and solvents used as received. In particular, ligands HL1-5 were purchased 
from Sigma Aldrich. The starting complex, [RuCl2(bpy)2] was synthesized according to a 
previously described but slightly modified synthetic route [1,2]. 
Elemental analysis was performed on an Elemental Vario EL III microanalyzer and the results 
are presented within Tables 1-6. A Nicolet 6700 FT-IR spectrometer was used for recording 
infrared spectra. Signal intensities were reported with wavenumbers and denoted by the 
following abbreviations: vs = very strong, s = strong, m = medium, w = weak. LTQ Orbitrap XL 
Mass Spectrometer (Heated ESI) was used for recording all mass spectra in acetonitrile (HPLC 
grade) in a positive mode. The obtained peaks were assigned and interpreted according to 
dimensionless mass/charge ratio. 
1
H NMR spectra were recorded on a Bruker Avance III 500 
spectrometer in DMSO with TMS as the reference. For proton assignments, following 
abbreviations were used: (br) s = (broad) singlet, d = doublet, dd = doublet of doublets, t = 
triplet, q = quartet, p = pentet, m = multiplet (m) and Ar = aromatic protons. A rough estimation 
of the compounds' melting points was done using an electrothermal melting point apparatus. 
 
3.2. Syntheses   
 
3.2.1. Synthesis of the starting ruthenium complex, [RuCl2(bpy)2] 
 
 The synthesis was performed according to a slightly modified method of Sullivan-a
 
[1]. 
RuCl3·xH2O (1.30 g, 5 mmol), 2,2’–bipyridine (1.56 g, 10 mmol) and LiCl (2.1 g, 50 mmol) 
were added in 12.5 mL DMF and refluxed for 8 h with stirring. Afterwards, the solution was 
cooled to room temperature and 100 mL of a mixture of acetone/water (1:1) was added. A green-
black solid was separated by filtration. The solid was added into 100 mL water and stirred for 10 
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h at r.t. followed by filtration. The product was then washed three times with 12.5 mL of water 
and ether.  
The yield was 80% based on the ruthenium salt; IR (cm
–1
): 3491.4(w), 3098.9(w), 3068.5(w), 
3037.6(w), 1604.4(m), 1450.4(m), 1417.3(m), 1261.4(m), 1014.3(m), 762.0(s). 
 
Table 1. Elemental analysis of the starting ruthenium complex.  
 
Element 
 
Anal. calcd for C20H16N4Cl2Ru∙1.5 H2O (%): Found (%) 
 
C 
 
47.72 47.89 
 
H 
 
3.80 3.59 
 
N 
 
11.13 11.13 
 
 
3.2.2. Synthesis of complex 1, [Ru(L1)(bpy)2]PF6 
 
 [RuCl2(bipy)2] (100 mg, 0.21 mmol) was dissolved in ethanol (15 mL) and stirred for 20 
min at 40 ºC. The ligand, 3-methylpyridine-2-carboxylic acid, HL1 (28.3 mg, 0.21 mmol) was 
dissolved in a small volume of ethanol (5 mL) and added to the solution of the starting complex. 
In the following 3 hours the reaction mixture was stirred under reflux and afterwards left to cool 
to room temperature. After adding an equimolar amount of a counterion, NH4PF6 (33.7 mg, 0.21 
mmol), dark red precipitate was isolated by filtration. The crude product was washed with a 
small amount of water and diethyl ether. 
 
(1): Yield: 71 %. 
1
H NMR (500 MHz, DMSO-d6): δ 8.81 (dd, 2H, Ar), 8.75-8.69 (m, 3H, Ar), 
8.16 (q, 2H, Ar), 7.98 (p, 2H, Ar), 7.83-7.78 (m, 4H, Ar), 7.64 (t, 1H, Ar), 7.54 (br s, 1H, Ar), 
7.39-7.33 (m, 4H, Ar), 2.67 (s, 3H, −CH3). 
13
C NMR (125.80 MHz, DMSO-d6): 171.86 (C═O), 
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157.41, 156.98, 151.37, 150.74, 140.79, 139.18, 136.81, 136.66, 136.40, 135.53, 127.46, 127.30, 
126.97, 126.89, 126.53, 124.12, 123.76, 123.67, 123.46, 56.01, 19.45 and 18.54 (−CH3). IR (cm
–
1
): 3423.2 (w), 1645.0 (s), 1446.8 (m), 1333.6 (m), 1268.0 (w), 1239.1 (w), 839.8 (vs), 766.2 (s), 
730.7 (w), 558.2 (s). ESI-MS (m/z, (relative abundance, %)): 550.08 [M
+
-PF6
−
, 100]. M.p.: above 
300 ºC. 
 
 
Table 2. Elemental analysis of the complex 1. 
 
Element 
 
Anal. calcd for C27H22N5O2RuPF6∙0.5 H2O (%): Found (%) 
 
C 
 
46.09 45.55 
 
H 
 
3.30 3.44 
 
N 
 
9.95 9.53 
 
 
3.2.3. Synthesis of complex 2, [Ru(L2)(bpy)2]PF6 
 
 [RuCl2(bipy)2] (100 mg, 0.21 mmol) was dissolved in ethanol (15 mL) and stirred for 20 
min at 40 ºC. The ligand, 6-methylpyridine-2-carboxylic acid, HL2 (28.3 mg, 0.21 mmol) was 
dissolved in a small volume of ethanol (5 mL) and added to solution of the starting complex. In 
the following 3 hours the reaction mixture was stirred under reflux and afterwards left to cool to 
room temperature. After adding an equimolar amount of a counterion, NH4PF6 (33.7 mg, 0.21 
mmol), dark red precipitate was isolated by filtration. The crude product was washed with a 
small amount of water and diethyl ether. 
 
(2): Yield: 65 %. 
1
H NMR (500 MHz, DMSO-d6): δ 8.82 (br t, 2H, Ar), 8.19 (br t, 2H, Ar), 8.08 
(br s, 1H, Ar), 7.99 (sept, 2H, Ar), 7.94−7.85 (m, 4H, Ar), 7.82-7.78 (m, 2H, Ar), 7.62 (br t, 2H, 
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Ar), 7.50-7.30 (m, 4H, Ar), 1.68 (s, 3H, −CH3).
 13
C NMR (125.80 MHz, DMSO-d6): 172.03 
(C═O), 157.71, 157.43, 157.31, 153.70, 151.95, 151.07, 148.92, 137.94, 137.89, 136.72, 135.23, 
129.04, 127.84, 127.42, 127.14, 126.83, 125.41, 125.37, 124.49, 123.83, 123.42, 23.62 (−CH3).  
 IR (cm
–1
): 3089.3 (w), 1650.4 (m), 1604.0 (m), 1466.8 (m), 1450.0 (m), 1159.3 (w), 840.5 (vs), 
766.6 (s), 557.3 (s). ESI-MS (m/z, (relative abundance, %)): 550.08 [M
+
-PF6
−
, 100]. M.p.: above 
300 ºC. 
 
 
Table 3. Elemental analysis of the complex 2. 
 
Element 
 
Anal. calcd for C27H22N5O2RuPF6 (%): Found (%) 
 
C 
 
46.69 46.33 
 
H 
 
3.19 3.28 
 
N 
 
10.08 9.84 
 
 
 
3.2.4. Synthesis of complex 3, [Ru(L3)(bpy)2]PF6 
 
 [RuCl2(bipy)2] (100 mg, 0.21 mmol) was dissolved in ethanol (15 mL) and stirred for 20 
min at 40 ºC. The ligand, 5-bromopyridine-2-carboxylic acid (41.7 mg, 0.21 mmol), HL3 was 
dissolved in a small volume of ethanol (5 mL) and added to solution of the starting complex. In 
the following 3 hours the reaction mixture was stirred under reflux and afterwards left to cool to 
room temperature. After adding an equimolar amount of a counterion, NH4PF6 (33.7 mg, 0.21 
mmol), dark red precipitate was isolated by filtration. The crude product was washed with a 
small amount of water and diethyl ether. Recrystallization of the amorphous product from an 
EtOH-ACN mixture gave deep red crystals suitable for X-ray analysis. 
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(3): Yield: 63 %. 
1
H NMR (500 MHz, DMSO-d6): δ 8.82 (t, 2H, Ar), 8.74 (br q, 2H, Ar), 8.68 
(d, 2H, Ar), 8.21 (p, 4H, Ar), 8.11 (d, 1H, Ar), 8.06-7.95 (m, 1H, Ar), 7.87 (dd, 1H, Ar), 7.80 (t, 
1H, Ar), 7.64 (t, 1H, Ar), 7.55 (d, 1H, Ar), 7.51 (s, 1H, Ar), 7.38 (br t, 2H, Ar). 
13
C NMR 
(125.80 MHz, DMSO-d6): 170.63 (C═O), 158.53, 157.47, 157.18, 156.95, 152.36, 151.49, 
137.12, 137.03, 135.84, 127.68, 127.48, 127.02, 126.72, 124.29, 124.04, 123.97, 123.80, 123.58. 
IR (cm
–1
): 3080.5 (w), 1647.5 (s), 1603.4 (m), 1447.1 (m), 1373.7 (w), 1327.4 (w), 1160.5 (w), 
1027.2 (w), 840.8 (vs), 767.9 (s), 727.5 (m), 556.0 (s), 506.1 (w). ESI-MS (m/z, (relative 
abundance, %)): 615.97 [M
+
-PF6
−
, 100]. M.p.: above 300 ºC. 
 
 
Table 4. Elemental analysis of the complex 3. 
 
Element 
 
Anal. calcd for C26H19N5O2RuBrPF6 (%): Found (%) 
 
C 
 
41.12 40.75 
 
H 
 
2.52 2.63 
 
N 
 
9.22 9.38 
 
 
3.2.5. Synthesis of complex 4, [Ru(L4)(bpy)2]PF6 
 
 [RuCl2(bipy)2] (100 mg, 0.21 mmol) was dissolved in ethanol (15 mL) and stirred for 20 
min at 40 ºC. The ligand, 6-bromopyridine-2-carboxylic acid HL4 (41.7 mg, 0.21 mmol) was 
dissolved in a small volume of ethanol (5 mL) and added to solution of the starting complex. In 
the following 3 hours the reaction mixture was stirred under reflux and afterwards left to cool to 
room temperature. After adding an equimolar amount of a counterion, NH4PF6 (33.7 mg, 0.21 
mmol), dark red precipitate was isolated by filtration. The crude product was washed with a 
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small amount of water and diethyl ether. Recrystallization of the amorphous product from an 
EtOH-ACN mixture gave deep red crystals suitable for X-ray analysis. 
 
(4): Yield: 38 %. 
1
H NMR (500 MHz, DMSO-d6): δ 8.84 (t, 2H, Ar), 8.76-8.71 (m, 2H, Ar), 8.65 
(dd, 2H, Ar), 8.39 (t, 1H, Ar), 8.33 (d, 1H, Ar), 8.26-8.20 (m, 1H, Ar), 8.09-7.78 (m, 4H, Ar), 
7.68 (t, 1H, Ar), 7.43 (d, 1H, Ar), 7.38 (t, 1H, Ar), 7.34 (t, 1H, Ar), 7.27 (t, 1H, Ar), 7.17 (d, 1H, 
Ar).
 13
C NMR (125.80 MHz, DMSO-d6): 171.18 (C═O), 157.94, 157.35, 153.19, 152.32, 151.59, 
149.35, 139.94, 138.59, 138.52, 137.14, 137.03, 136.88, 135.58, 134.22, 127.56, 127.13, 126.80, 
126.54, 125.95, 123.97, 123.85, 123.61, 123.52. IR (cm
–1
): 3091.3 (w), 1647.4 (m), 1604.9 (w), 
1449.8 (m), 840.9 (vs), 766.2 (s), 556.8 (m). ESI-MS (m/z, (relative abundance, %)): 615.97 
[M
+
-PF6
−
, 100]. M.p.: above 300 ºC. 
 
 
Table 5. Elemental analysis of the complex 4. 
 
Element 
 
Anal. calcd for C26H19N5O2RuBrPF6 (%): Found (%) 
 
C 
 
41.12 40.83 
 
H 
 
2.52 2.75 
 
N 
 
9.22 9.22 
 
 
3.2.6. Synthesis of complex 5, [Ru(L5)(bpy)2]PF6 
 
[RuCl2(bipy)2] (100 mg, 0.21 mmol) was dissolved in ethanol (15 mL) and stirred for 20 
min at 40 ºC. The ligand, 2,4-pyridinedicarboxylic acid HL5 (35 mg, 0.21 mmol) was dissolved 
in a small volume of ethanol (5 mL) and added to solution of the starting complex. In the 
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following 3 hours the reaction mixture was stirred under reflux and afterwards left to cool to 
room temperature. After adding an equimolar amount of a counterion, NH4PF6 (33.7 mg, 0.21 
mmol), dark red precipitate was isolated by filtration. The crude product was washed with a 
small amount of water and diethyl ether. 
 
(5): Yield: 74 %. 
1
H NMR (500 MHz, DMSO-d6): 8.84-8.81 (m, 2H, Ar-H), 8.76 (t, 2H, Ar-H), 
8.69 (d, 1H, Ar-H),8.25 (d, 1H, Ar-H), 8.19 (t, 2H, Ar-H), 8.02 (p, 2H, Ar-H), 7.97 (d, 1H, Ar-
H), 7.84-7.78 (m, 3H, Ar-H), 7.72 (d, 1H, Ar-H), 7.62-7.60 (m, 2H, Ar-H), 7.39 (p, 2H, Ar-H). 
IR (cm
–1
): 3089 (w), 1605 (m), 1469 (m), 1450 (m), 1315 (w), 1161 (w), 1030 (w), 840 (s), 767 
(s), 727 (w), 556 (m). ESI-MS (m/z, (relative abundance, %)): 580.05 [M
+
-PF6
−
, 100]. M.p.: 
above 300 ºC. 
 
 
Table 6. Elemental analysis of the complex 5. 
 
Element 
 
Anal. calcd for C27H20N5O4RuPF6·0.5H2O (%): Found (%) 
 
C 
 
44.21 43.83 
 
H 
 
2.89 2.87 
 
N 
 
9.55 9.59 
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3.3. X-ray structure determinations 
 
3.3.1. X-ray analysis of the complexes 
 
 For the reported structures, X-ray intensity data were collected, at 100 K, on an Agilent 
Supernova Dual Source (Cu at zero) diffractometer equipped with an Atlas CCD detector using 
 scans and CuK ( = 1.54184 Å) radiation. The images were interpreted and integrated with 
the program CrysAlisPro (Rigaku Oxford Diffraction) [3]. Using Olex2 [4], the structures were 
solved by direct methods using the ShelXS structure solution program and refined by full-matrix 
least-squares on F
2
 using the ShelXL program package [5]. Non-hydrogen atoms were 
anisotropically refined and the hydrogen atoms in the riding mode and isotropic temperature 
factors fixed at 1.2 times U(eq) of the parent atoms (1.5 times U(eq) for methyl and hydroxyl 
groups). The hydrogen atoms of the solvent water molecule and the pyridine-2-carboxylate-4-
carboxylic acid carboxyl group were located from a difference Fourier electron density map and 
restrained refined with isotropic temperature factors fixed at 1.5 times U(eq) of the parent atoms.  
CCDC 1482372-1482373 and 1524673 contain the supplementary crystallographic data for this 
paper and can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from 
the Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB2 1EZ, UK; fax: 
+44-1223-336033; or deposit@ccdc.cam.ac.uk). Crystal data and structure refinement for the 
complexes 3, 4 and 5, are shown in the Tables 7, 8, 9. 
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Table 7. Crystal data and structure refinement for the complex 3. 
Empirical formula C26H19N5O2RuBrPF6 
Formula weight 851.54 
Temperature (K) 100 
Crystal system Monoclinic 
Space group P21/n 
a(Å) 11.0258(2) 
b(Å) 14.1182(3) 
c(Å) 20.8563(5) 
α(°) 90 
β(°) 92.332(2) 
γ (°) 90 
V(Å
3
) 3243.90(12) 
Z 4 
calc (g cm
-3
) 1.744 
μ(Cu-Kα, mm-1) 6.531 
F(000) 1704 
h,k,l 15,17,19 
Nref 6531 
Rint 0.0731 
R1 0.0368 
wR2 0.0993 
Reflections collected 31031 
Θ(max) 75.255 
 
 
 
 
 
 
30 
 
Table 8. Crystal data and structure refinement for the complex 4. 
Empirical formula C26H19N5O2RuBrPF6 
Formula weight 759.40 
Temperature (K) 100 
Crystal system Monoclinic 
Space group I2/A 
a(Å) 18.0576(9) 
b(Å) 18.0576(9) 
c(Å) 21.4772(13) 
α(°) 90 
β(°) 109.681(6) 
γ (°) 90 
V(Å
3
) 5213.9(5) 
Z 8 
calc (g cm
-3
) 1.935 
μ(Cu-Kα, mm-1) 7.977 
F(000) 2992 
h,k,l 22,17,26 
Nref 5079 
Rint 0.0440 
R1 0.0462 
wR2 0.1368 
Reflections collected 14143 
Θ(max) 75.762 
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Table 9. Crystal data and structure refinement for the complex 5. 
Empirical formula C27H22F6N5O5PRu 
Formula weight 742.54 
Temperature (K) 100 
Crystal system Monoclinic 
Space group P21/n 
a(Å) 12.4042(3) 
b(Å) 14.3080(5) 
c(Å) 15.9245(5) 
α(°) 90 
β(°) 98.475(3) 
γ (°) 90 
V(Å
3
) 2795.41(15) 
Z 4 
calc (g cm
-3
) 1.764 
μ(Cu-Kα, mm-1) 5.895 
F(000) 1488 
h,k,l 15,17,19 
Nref 5603 
Rint 0.0520 
R1 0.0427 
wR2 0.1077 
Reflections collected 17213 
Θ(max) 75.501 
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3.4. Electrochemical measurements 
 
 Electrochemical measurements were performed with a CHI-760B instrument at room 
temperature. A three electrode system consisted of a boron doped diamond electrode (Windsor 
Scientific Ltd, Slough, Berkshire, United Kingdom) embedded in a polyether ether ketone 
(PEEK) body with an inner diameter of 3 mm, a resistivity of 0.075 Ω cm and a boron doping 
level of 1000 ppm (as declared by the supplier) used as working electrode, a non-aqueous 
Ag/AgCl electrode used as the reference electrode and a platinum wire that was used as a counter 
electrode in the potential range of −2.3 V to 1.0 V. For the purpose of experiments, 1.0 mM 
solutions of the synthesized complexes in DMSO were prepared and TBAP was added as a 
supporting electrolyte. Cyclic voltammograms were obtained at 20 mV s
−1
 for 1-4; 50, 100, 150, 
200, 300, 500 mV s
−1 
for 4.  
For the complex 5 the voltammetric measurement was performed in a three-electrode cell, which 
consisted of a glassy carbon electrode (Model 6.1204.300), an auxiliary platinum electrode with 
large surface area (Model CHI221, cell top including platinum wire counter electrode) and an 
Ag/AgCl reference electrode (Model CHI111). Cyclic voltammograms were obtained at 20 mV 
s
−1
 for 25, 50, 100, 150, 200 and 300 mV s
−1
. 
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3.5. Biology tests 
 
3.5.1. Reagents and cell cultures 
 
Human cervical adenocarcinoma (HeLa), human alveolar basal adenocarcinoma (A549), 
human colon cancer (LS-174), human chronic myelogenous leukaemia (K562) and human fetal 
lung fibroblast (MRC-5) cell lines were maintained as a monolayer culture in the Roswell Park 
Memorial Institute (RPMI) 1640 nutrient medium (Sigma Aldrich). The nutrient medium was 
supplemented with 10% heat inactivated fetal calf serum (FCS) (Sigma Aldrich), 4-(2-
hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) (25 mM), penicillin (100 units/mL), 
streptomycin (200 g/mL), and L-glutamine (3 mM). Cells were maintained as a monolayer 
culture in tissue culture flasks (Thermo Scientific Nunc™), in an incubator at 37 °C, in a 
humidified atmosphere composed of 5% CO2.  
 
3.5.2. MTT cytotoxicity assay 
 
 The antiproliferative activity of the tested complexes was determined using the 3-(4,5-
dymethylthiazol-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma Aldrich) assay [6]. Cells 
were seeded into 96-well cell culture plates (Thermo Scientific Nunc™), in number of 4000 c/w 
(HeLa), 5000 c/w (K562), 7000 c/w (LS-174 and MRC-5) and 8000 c/w (A549), in 100 µl of 
culture medium. After 24 h of growth, cells were exposed to the serial dilutions of tested agents. 
Stock solutions were prepared immediately prior to use by dissolving in dimethyl sulfoxide 
(DMSO), so that the DMSO content did not exceed 1% (v/v). The antiproliferative effect of the 
complexes and ligand was evaluated in a range of concentrations up to 200 µM, for 72 h of 
continuous drug action. After the treatment, 20 µL of MTT solution, 5 mg/mL in phosphate 
buffer solution (PBS), pH 7.2, was added to each well. The samples were incubated for 4 h at 37 
°C with 5% CO2 in humidified atmosphere. Formazan crystals were dissolved in 100 µl of 10% 
sodium dodecyl sulfate (SDS). The absorbance was recorded on a microplate reader 
(ThermoLabsystems Multiskan EX 200e240 V) after 24 h at a wavelength of 570 nm. The IC50 
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value (µM) was defined as the concentration of a drug which produces 50% inhibition of cell 
survival and was determined based on the cell survival diagrams. 
 
3.5.3. Combinational drug study 
 
 Reagents N-acetyl-L-cysteine (NAC) and L-Buthionine-sulfoximine (L-BSO) were 
purchased from Sigma-Aldrich. NAC and L-BSO were dissolved in a physiological saline 
solution, at a final concentration of 30 mM, and sterilized by filtration (0.2 μm pore-size filters). 
The stock solutions were wrapped in foil and kept at -20 ˚C. 
 
3.5.4. Effects of N-acetyl-L-cysteine (NAC) or L-Buthionine-sulfoximine (L-BSO) on complex 
2 - treated HeLa cells in relation to cell survival 
 
 In the combinational study, L-Buthionine-sulfoximine (L-BSO) or N-acetyl-L-cysteine 
(NAC) was used in pre-treatment with the selected complex 2. Briefly, HeLa cells were pre-
treated with subtoxic concentrations of L-BSO (1 μM) or NAC (20 µM) for 3 h, and after 
washing out, the treatment continued with tested complex 2 alone, applied in selected 
concentrations (50, 100, 200 µM). Viability of HeLa cells, after 72 h of continual treatment with 
the tested complex 2 alone, or in combination with NAC (20 µM)/L-BSO (1 μM), was measured 
by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay, as previously 
described. 
 
3.5.5. Effects of N-acetyl-L-cysteine (NAC) or L-Buthionine-sulfoximine (L-BSO) on complex 
2 -treated HeLa cells in relation to cell cycle perturbations 
 
 Cell cycle phase distribution analysis was performed by flow-cytometry of the DNA 
content in fixed HeLa cells, after staining with propidium iodide (PI) [7]. The cells were seeded 
at a density of 2 x 10
5
 cells/well in 6-well plates and growth in nutrition medium. After 24 h, the 
cells were exposed to NAC (20 µM) or L-BSO (1 μM) for 3 h, and after washing out, the cells 
were continually exposed to the investigated complex 2 for 48 h with IC50 (132 μM) 
concentration. Control cells were incubated only in nutrient medium. After 48 h of continual 
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treatment, the cells were collected by trypsinization, washed twice with ice-cold PBS, and fixed 
for 30 min in 70% EtOH. After fixation, the cells were washed again with PBS, and incubated 
with RNaseA (1 mg/mL) for 30 min at 37 °C. The cells were then stained with PI (at 
concentration of 400 µg/mL) 15 min before flow-cytometric analysis. Cell cycle phase 
distributions were analyzed using a fluorescence activated cell sorting (FACS) Calibur Becton 
Dickinson flow cytometer and Cell Quest computer software. 
 
3.6. DNA-binding studies 
 
 DNA (isolated from salmon testes) was purchased from Sigma Aldrich. The studies were 
performed for complex 2. 
 
3.6.1. UV-vis study 
 
 The absorption titration measurements were performed using a Varian spectrophotometer 
in the wavelength range from 300-800 nm. The complex concentration was fixed at 20 ppm in 
PBS at pH 7, and titration was done with different aliquots of DNA standard solution to make 
DNA concentrations of 0, 20, 50, 100, 150 and 250 ppm. After preparing complex-DNA 
solutions they were allowed to incubate for 5 min at room temperature before the adsorption 
spectra were recorded. 
 
3.6.2. Cyclic voltammetry interaction study  
 
 Cyclic voltammetry measurements were done in the same concentration range 0-250 ppm 
of the DNA presented in the phosphate buffer solution of the 20 ppm of complex 2. The 
voltammetric measurements were performed using a potentiostat/galvanostat (AUTOLAB 
PGSTAT 302 N, Metrohm Autolab B.V., The Netherlands) controlled by the corresponding 
electrochemical software (NOVA 1.9). The cell (10 mL) consisted of a three-electrode system, a 
boron-doped diamond electrode (Windsor Scientific Ltd, Slough, Berkshire, United Kingdom) 
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embedded in a polyether ether ketone (PEEK) body with an inner diameter of 3 mm, a resistivity 
of 0.075 Ω cm and a boron doping level of 1000 ppm (as declared by the supplier) as a working 
electrode, an Ag/AgCl (saturated KCl) as a reference electrode and a Pt wire as a counter 
electrode. All potentials reported in this paper are referred versus the Ag/AgCl (saturated KCl) 
reference electrode. Also, all experiments were done at ambient temperature after 5 min of 
incubation period. 
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4. RESULTS AND DISCUSSION 
 
4.1. Synthesis and characterization 
 
 The general procedure of all the synthesized complexes included dissolving of the metal 
precursor and equimolar amount of the ligand in ethanol (Scheme 1).  
The reaction mixture was refluxed for 3 h and then left to cool to room temperature. After adding 
the appropriate amount of NH4PF6 to the solution, the intensive color change from dark purple to 
dark red was observed. Isolated amorphous precipitate was rinsed with a small amount of water 
and diethyl ether. Obtained compounds were air stable and showed no traces of decomposition. 
Concerning their solubility, complexes 1-5 were soluble in some polar (e.g., DMSO, CHCl3, 
CH2Cl2, CH3CN) and nonsoluble in apolar solvents with a significant remark for 1 and 2, which 
are very soluble in water. 
 
 
 
Scheme 1: Synthesis of [RuL(bpy)2]PF6 complexes 1-5. 
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 IR spectra of synthesized complexes 1-5, generally revealed an asymmetric stretching 
vibration that originates from the C=O bond and is located between 1645.0 and 1650.4 cm
−1
 
(1645.0 cm
−1
 for complex 1; 1650.4 cm
−1
 for complex 2; 1647.5 cm
−1
 for complex 3; 1647.4 
cm
−1
 for complex 4). The coordination of the metal center via oxygen is suggested by 
comparison to the band of the free carboxylic group at ~ 1700 cm
−1
 in the spectra of the 
corresponding ligand(s). The very intensive vibration found at 840 cm
−1
 is assigned to C−H 
stretching modes.  
 In the ESI-MS spectra of 1-5 recorded in acetonitrile, the [M
+
-PF6
−
] signal was detected 
(at m/z: 550.08 for complexes 1 and 2; 615.97 for complexes 3 and 4; 580.05 for complex 5)  
 As for 
1
H NMR assignation, all products share a common structural feature, i.e. aromatic 
protons originating from pyridine and bipyridyl moieties. In the 
1
H NMR spectra of 1 and 2, the 
CH3− group in position 3 and 6, show well-defined singlets at 2.67 and 1.68 ppm, respectively.  
In the 
1
H NMR spectrum of the complex 5, carboxylic protons were not detected because the co-
ligand is coordinated to ruthenium through the oxygen atom of the carboxylic group in position 2 
of the pyridine ring, while the carboxylic group in position 4 was deprotonated in DMSO. 
 In the 
13
C NMR spectra of complexes 1-4 all aromatic carbons were detected in the 
range: 158.53-123.42 ppm, while the carbons from C=O group were detected at 171.86 ppm (1), 
172.03 ppm (2), 170.63 (3), 171.18 (4). 
 
4.2. Description of the crystal structures 
 
 The complex 3 crystallized in the monoclinic centro-symmetric space group P21/n and the 
asymmetric unit contains one [Ru(5-bromopyridine-2- carboxylate)(bpy)2]
+
 complex cation, one 
PF6
 –
 counter anion and two ethanol solvent molecules. The Ru
2+
 ion is coordinated by five N-
atoms and one O-atom and the coordination environment around the Ru
2+
 center can be 
described as a distorted octahedron. The Ru-N(bpy) distances in the range of 2.042(2)-2.058(3) 
Å, while the Ru-N(L) and Ru-O distances are 2.070(2) Å and 2.095(2) Å, respectively (Figure 
11, Table 10). 
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Figure 11. Molecular structure of the cation of complex 3, showing thermal displacement ellipsoids at the 50% 
probability level and atom labeling scheme of the hetero-atoms. The PF6  counter anion and two solvent EtOH 
molecules are omitted for clarity. 
 
The pairs of pyridine rings in the two bpy ligands are almost planar and show dihedral angles of 
4.01(16)° and 1.70(15)°, respectively (between least-squares planes through the respective 
rings). 
The pyridine bromine atom forms C-Br∙∙∙π interactions with the symmetry-equivalent pyridine 
ring N3/C11-C15 (C-Br∙∙∙centroid distance of 3.6545(14) Å). 
In the packing, several π-π stacking interactions are observed between the five pyridine rings 
(centroid∙∙∙centroid distances in the range of 3.7820(18)-5.9751(18) Å). Additionally, C-H∙∙∙π 
interactions are observed between C29(H) and pyridine ring N1/C1-C5(C(H)∙∙∙centroid distances 
of 3.508(4) Å). 
The crystal packing is stabilized by several hydrogen bonds, i.e. between the 5-bromopyridine-2-
carboxylate O2 atom and an ethanol solvent molecule (O3(H)∙∙∙O2 = 2.723(4) Å), between the 
two ethanol solvent molecules (O4(H)∙∙∙O3 = 2.874(4) Å) and a longer hydrogen bond between 
the 5-bromopyridine-2-carboxylate Br1 atom and the latter ethanol molecule (O4(H)∙∙∙Br1 = 
3.466(3) Å) (Figure 12). 
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Figure 12. Packing in the crystal structure of complex 3, along the a-axis. Hydrogen bonds, formed between 
bromine and carboxylate oxygen atoms of the 5-bromopyridine-2-carboxylate and ethanol solvent molecules, are 
indicated. 
 
The compound 4 crystallized in the monoclinic centro-symmetric space group I2/a and the 
asymmetric unit contains one [Ru(6-bromopyridine-2- carboxylate)(bpy)2]
+
 complex cation and 
one PF6 
–
 counter anion. Analogous to complex 3, the Ru center is coordinated in a distorted 
octahedral manner, by five N-atoms and one O-atom, with the Ru-N(bpy) distances in the range 
of 2.046(4)-2.056(4) Å, which is comparable with symmetrical Ru(bpy)3 complexes in the 
Cambridge Structural Database (CSD, Version 5.37, 2016) [1], while the Ru-N(L) distance is 
longer (2.123(4) Å) and the Ru-O distance is 2.077(4) Å (Figure 13, Table 11). 
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Figure 13. Molecular structure of the cation of complex 4, showing thermal displacement ellipsoids at the 50% 
probability level and atom labeling scheme of the hetero-atoms. The PF6   counter anion is omitted for clarity. 
 
The pairs of pyridine rings in the two bpy ligands are also almost planar and show dihedral 
angles of 4.6(3)° and 5.7(3)°, respectively (between least-squares planes through the respective 
rings).  
The pyridine bromine atom forms C-Br∙∙∙π interactions with pyridine ring N2/C6-C10 and the 
symmetry-equivalent pyridine ring N3/C11-C15 (C-Br∙∙∙centroid distance of 3.477(2) Å and 
3.887(2) Å, respectively). 
In the packing, several π-π stacking interactions are observed between the five pyridine rings 
(centroid∙∙∙centroid distances in the range of 4.276(3)-5.866(3) Å). 
Additionally, C-H∙∙∙π interactions are observed between C5(H) and C12(H) and pyridine rings 
(C(H)∙∙∙centroid distances of 3.729(6) Å and 3.553(6) Å, respectively). 
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      Table 10. Selected bond lengths (Å) and angles (°) for compound 3 
Selected bond lengths(Å) 3 
Ru1-N1 2.055(3) 
Ru1-N2 2.042(3) 
Ru1-N3 2.070(3) 
Ru1-N4 2.058(3) 
Ru1-N5 2.069(3) 
Ru1-O1 2.095(2) 
Selected bond angles(°) 3 
N2-Ru1-N5 94.72(10) 
N2-Ru1-N3 97.81(11) 
N2-Ru1-N4 96.18(10) 
N2-Ru1-N1 79.15(11) 
N5-Ru1-O1 79.83(10) 
N5-Ru1-N3 96.24(10) 
N3-Ru1-O1 89.62(10) 
N4-Ru1-O1 89.74(10) 
N4-Ru1-N3 78.85(10) 
N1-Ru1-O1 93.87(10) 
N1-Ru1-N5 89.31(10) 
N1-Ru1-N4 96.14(10) 
 
 
      Table 11. Selected bond lengths (Å) and angles (°) for compound 4. 
Selected bond lengths(Å) 4 
Ru1-N1 2.046(4) 
Ru1-N2 2.056(4) 
Ru1-N3 2.053(4) 
Ru1-N4 2.048(4) 
Ru1-N5 2.123(4) 
Ru1-O1 2.077(4) 
Selected bond angles(°) 4 
N2-Ru1-N5 103.36(16) 
N2-Ru1-N3 98.65(17) 
N2-Ru1-N4 92.75(16) 
N2-Ru1-N1 78.96(16) 
N5-Ru1-O1 79.68(14) 
N5-Ru1-N3 90.34(16) 
N3-Ru1-O1 87.35(16) 
N4-Ru1-O1 85.15(15) 
N4-Ru1-N3 79.50(17) 
N1-Ru1-O1 94.80(15) 
N1-Ru1-N5 94.67(16) 
N1-Ru1-N4 95.97(16) 
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 The compound 5 crystallized in the centro-symmetric space group P21/n, with one 
[RuL(bpy)2]PF6 complex in the asymmetric unit, together with one water solvent molecule 
(Figure 14). The Ru(II) ion is octahedrally coordinated by four nitrogen atoms from the two 
bipyridine ligands, and one nitrogen and one oxygen atom from the pyridine-2-carboxylate-4-
carboxylic acid. In fact, while the coordinating carboxyl group in position 2 of the 2,4-
dicarboxylic acid ligand is deprotonated, the other carboxyl group in position 4 is clearly 
protonated. The Ru(II)-Nbpy distances are in the range of 2.031(4)-2.055(4) Å, while the Ru(II)-
NL and Ru(II)-OL distances are 2.049(3) Å and 2.090(3) Å, respectively. The N-Ru-N/O angles 
vary between 79.07(13)° and 99.05(13)°. 
 
 
 
Figure 14. Asymmetric unit of the crystal structure of complex 5, consisting of one [RuL(bpy)2]PF6 complex and 
one water solvent molecule, with atom-labeling scheme of the hetero-atoms (except for the PF6
-
 ion). Thermal 
displacement ellipsoids are drawn at the 50% probability level. 
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 In the crystal packing, hydrogen bonds are formed between the pyridine-2-carboxylate-4-
carboxylic acid groups and the water solvent molecule. Each water molecule forms a hydrogen 
bond with the deprotonated carboxylic group [O5(-H5A)∙∙∙O2 = 2.692(4) Å] and with the 
protonated carboxylic groups of two symmetry-equivalent Ru(II) complexes [O5(-H5B)∙∙∙O3i = 
2.822(4) Å and O5∙∙∙(H4-)O4ii = 2.552(4) Å; symmetry codes: (i) 1/2 + x, 3/2 - y, 1/2 + z; (ii) 3/2 
- x, -1/2 + y, 1/2 - z], connecting four Ru(II) complexes over an inversion center (Figure 15). 
Furthermore, multiple π-π stacking interactions are observed between the aromatic bipyridine 
rings and the pyridine-2-carboxylate-4-carboxylic acid rings [ring centroid-centroid distances 
between 4.218(2) and 5.665(2) Å]. Selected bond lengths (Å) bond angles (°) for complex 5 are 
shown in the Tables 12 and 13. 
 
 
 
 
Figure 15. Part of the crystal packing of the structure of complex 5, along the c-axis, showing hydrogen bonds 
between the water solvent molecules and the pyridine-2-carboxylate-4-carboxylic acid groups, with atom-labeling 
scheme of specific atoms involved. Symmetry codes: (i) 1/2 + x, 3/2 - y, 1/2 + z; (ii) 3/2 - x, -1/2 + y, 1/2 - z. 
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Table 12. Selected bond lengths (Å) for compound 5. 
Atom Atom   Length/Å          Atom    Atom  Length/Å  
Ru1 O1 2.090(3) C6 C7 1.393(5) 
Ru1 N1 2.053(3) C7 C8 1.382(6) 
Ru1 N2 2.031(3) C8 C9 1.387(6) 
Ru1 N3 2.054(3) C9 C10 1.384(6) 
Ru1 N4 2.056(4) C11 C12 1.393(6) 
Ru1 N5 2.049(3) C12 C13 1.377(7) 
O1 C21 1.279(5) C13 C14 1.379(7) 
O2 C21 1.235(5) C14 C15 1.375(6) 
O3 C27 1.213(5) C15 C16 1.470(6) 
O4 C27 1.319(5) C16 C17 1.376(6) 
N1 C1 1.344(5) C17 C18 1.393(7) 
N1 C5 1.366(5) C18 C19 1.365(7) 
N2 C6 1.365(5) C19 C20 1.375(6) 
N2 C10 1.354(5) C21 C22 1.515(5) 
N3 C11 1.351(5) C22 C23 1.366(6) 
N3 C15 1.368(5) C23 C24 1.399(5) 
N4 C16 1.366(5) C24 C25 1.393(6) 
N4 C20 1.346(5) C24 C27 1.492(6) 
N5 C22 1.368(5) C25 C26 1.378(6) 
N5 C26 1.346(5) P1 F1 1.551(4) 
C1 C2 1.369(6) P1 F2 1.571(3) 
C2 C3 1.392(6) P1 F3 1.605(4) 
C3 C4 1.386(6) P1 F4 1.562(4) 
C4 C5 1.377(6) P1 F5 1.592(3) 
C5 C6 1.470(5) P1 F6 1.596(3) 
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Table 13. Selected bond angles (°) for complex 5. 
Atom Atom Atom    Angle/˚ Atom       Atom     Atom   Angle/˚ 
N1 Ru1 O1 95.76(12) N3 C11 C12 121.1(4) 
N1 Ru1 N3 98.62(13) C13 C12 C11 119.9(4) 
N1 Ru1 N4 177.05(13) C12 C13 C14 118.6(4) 
N2 Ru1 O1 173.99(12) C15 C14 C13 120.2(5) 
N2 Ru1 N1 79.07(13) N3 C15 C14 121.2(4) 
N2 Ru1 N3 91.27(13) N3 C15 C16 115.0(4) 
N2 Ru1 N4 99.03(13) C14 C15 C16 123.8(4) 
N2 Ru1 N5 97.22(13) N4 C16 C15 114.3(4) 
N3 Ru1 O1 92.55(11) N4 C16 C17 121.4(4) 
N3 Ru1 N4 79.10(14) C17 C16 C15 124.3(4) 
N4 Ru1 O1 86.25(12) C16 C17 C18 119.7(5) 
N5 Ru1 O1 79.38(12) C19 C18 C17 118.4(5) 
N5 Ru1 N1 87.69(13) C18 C19 C20 120.0(5) 
N5 Ru1 N3 170.27(13) N4 C20 C19 122.4(5) 
N5 Ru1 N4 94.81(14) O1 C21 C22 116.1(3) 
C21 O1 Ru1 115.6(2) O2 C21 O1 125.4(4) 
C1 N1 Ru1 125.7(3) O2 C21 C22 118.5(4) 
C1 N1 C5 118.3(4) N5 C22 C21 114.3(3) 
C5 N1 Ru1 115.7(3) C23 C22 N5 123.1(4) 
C6 N2 Ru1 115.7(3) C23 C22 C21 122.6(4) 
C10 N2 Ru1 125.7(3) C22 C23 C24 119.2(4) 
C10 N2 C6 118.6(3) C23 C24 C27 123.4(4) 
C11 N3 Ru1 125.8(3) C25 C24 C23 117.8(4) 
C11 N3 C15 118.9(4) C25 C24 C27 118.7(4) 
C15 N3 Ru1 115.3(3) C26 C25 C24 120.0(4) 
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C16 N4 Ru1 115.4(3) N5 C26 C25 122.4(4) 
C20 N4 Ru1 126.3(3) O3 C27 O4 124.5(4) 
C20 N4 C16 118.0(4) O3 C27 C24 122.2(4) 
C22 N5 Ru1 114.5(3) O4 C27 C24 113.3(3) 
C26 N5 Ru1 128.0(3) F1 P1 F2 91.3(3) 
C26 N5 C22 117.5(3) F1 P1 F3 178.8(2) 
N1 C1 C2 122.4(4) F1 P1 F4 92.3(3) 
C1 C2 C3 119.5(4) F1 P1 F5 90.72(18) 
C4 C3 C2 118.5(4) F1 P1 F6 90.30(19) 
C5 C4 C3 119.4(4) F2 P1 F3 87.7(2) 
N1 C5 C4 121.7(4) F2 P1 F5 90.1(2) 
N1 C5 C6 113.6(4) F2 P1 F6 90.1(2) 
C4 C5 C6 124.7(4) F4 P1 F2 176.4(3) 
N2 C6 C5 115.2(4) F4 P1 F3 88.7(3) 
N2 C6 C7 120.9(4) F4 P1 F5 90.0(2) 
C7 C6 C5 123.9(4) F4 P1 F6 89.68(19) 
C8 C7 C6 120.0(4) F5 P1 F3 88.45(18) 
C7 C8 C9 119.0(4) F5 P1 F6 178.94(19) 
C10 C9 C8 118.9(4) F6 P1 F3 90.53(18) 
N2 C10 C9 122.5(4)     
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4.3. Electrochemical measurements 
 
 For complexes 1-4 first reversible oxidation peaks were obtained in the potential range of 
E1/2 = −0.02 V to 0.04 V [2]. Also, these complexes showed a reversible oxidation peak at the 
potential range of E1/2 = 0.54 V to 0.64 V where peak potential shifts depend on the strength of 
the anionic ligand introduced in the Ru center. Additionally, complex 1 displayed one 
irreversible anodic peak at a potential of + 0.81 V which could be attributed to the oxidation of 
the ligand. In the negative range of potentials all complexes showed one reversible reduction 
couple in the range of E1/2 = −1.02 V to −1.03 V which could be assigned to the reduction of a 
bipyridyl moiety [2]. A second reversible reduction for all complexes was observed at around 
E1/2 = −1.65 V to −1.70 V, which could be considered also as reduction of a bipyridyl group. A 
third redox couple was observed at around E1/2 = −1.95 V to −2.01 V, which in the case of Br-
subunits (4 and 3) showed quasi-reversible behavior, and could be attributed to the third 
reduction of bipyridyl [3]. In the case of 4 the irreversible reduction peak at −2.23 V was not 
observed, which is obtained for all other complexes at the same potential, originating from the 
reduction of the R-ligands. 
The results obtained from electrochemical measurements are presented in Table 14 and 
representative voltammograms are given in Figure 16. 
 
Table 14. Electrochemical data for complexes 1-4 recorded in DMSO (0.1 M TBAP) at a boron doped diamond 
electrode with scan rate of 20 mV s
−1
. 
E1/2 / V (vs. Ag/AgCl) 
 positive potentials range negative potentials range 
 A1(ox/red) A2(ox/red) A3(ox/red) R1(ox/red) R2(ox/red) R3(ox/red) R4(ox/red) 
1 0.095/0.014 0.59/0.48 0.81 −1.03/−1.13 −1.64/−1.75 −1.89/−2.01 −2.23 
2 0.037/0.038 0.72/0.56 − −1.00/−1.04 −1.59/−1.68 −1.89/−1.96 −2.23 
3 0.04/0.039 0.64/0.058 − −/−1.09 −1.64/−1.68 −/−1.92 −2.20 
4 0.01/−0.04 0.66/0.48 − − −1.65/−1.76 −/−2.01 − 
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Figure 16. The cyclic voltammograms recorded in DMSO (0.1 mM TBAP) at a boron doped diamond working 
electrode a) for 1-4 with scan rate 20 mV s
−1
 and b) for 1 with scan rate 50, 100, 150, 200, 300, 500 mV s
−1
. 
 
 The electrochemical character of the complex 5 was studied by cyclic voltammetry in 
DMSO in the −2.50 < E < 1.00 V potential range (Figure 17). The recorded voltammograms 
show a reversible wave at ~0.30 V vs. Ag/AgCl, which can be readily assigned to the Ru(II)/(III) 
redox couple. The calculated ΔEp values tend to slightly increase with scan rate (from 100 mV to 
210 mV), indicating the partially reversible nature of the redox process. In the region of negative 
potentials (−2.35 < E < −1.15 V), multiple partially reversible peaks can be observed. This type 
of reductive activity can be assigned to the subsequent reductions of the bipyridyl moiety. In 
comparison to the literature data [4-6], the novel Ru(II) complex shows no exception concerning 
its electrochemical behavior. 
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Figure 17. The cyclic voltammograms for 5 recorded in DMSO (0.1 mM TBAP) at a glassy carbon electrode for 
scan rates 25, 50, 100, 150, 200 and 300 mV s
−1
. 
 
4.4. Results of MTT assay  
 
Cytotoxicity of the ruthenium complexes was determined by MTT assay, in few tumor cell lines: 
HeLa, LS-174, A549, K562, and one normal cell line, MRC-5, as presented in Table 15. 
Results, obtained after 72 h of drug continual action are presented in terms of IC50 values (μM), 
(Table 15). The complexes exhibited moderate cytotoxic activity in HeLa cells, with IC50 (μM), 
ranging from 132.26 ± 4.99 (2), to 184.02 ± 16.16 (3). Complex 2 with the highest cytotoxic 
activity in HeLa, also was the only one to exhibit cytotoxic activity in LS-174 cells, (180.90 ± 
10.12). For coordinatively saturated, as described in literature, substitutionally inert 
ruthenium(II) polypyridyl complexes, noncovalent association with cellular targets such as DNA, 
is generally assumed to be the primary mode of interaction with biological systems [7,8]. As 
compared to the first generations of platinum based drugs (cisplatin, oxaliplatin), ruthenium 
polypyridyl complexes posses structural properties that allow differential modes of binding to 
DNA, like specific covalent cross-linking [9], or intercalation between adjacent nucleobases. 
However, physicochemical parameters, such as complex stability, and ligand dissociation 
kinetics, also play important roles in determining their capability to reach target sites in the cell 
[10]. Few studies provided evidence that ruthenium polypyridyl complexes are transported to the 
interior of the cells, but may also remain associated with the cell membrane, particularly if they 
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carry extended and rigid polypyridyl ligands [11,12]. Sterically demanding ligands, such as 
polycyclic aromatic molecules (polypyridines), were shown to enhance cytotoxicity of the 
organoruthenium complexes, due to the hydrophobic interactions with DNA nucleobases or other 
targets in the cell. Moderate cytotoxicity of complexes 1-5 in the present study may be due to the 
greater off-target reactivity, when once in solution. Obtained IC50 values (μM) are significantly 
higher, in comparison to the IC50,values for cisplatin, reported in literature: 7.59 ± 0.04 (HeLa), 
10.86 ± 0.55 (K562), 17.20 ± 0.70 (A549), 11.54 ± 0.50 (MRC-5) [13]. Still, minor variations in 
the structure of the co-ligand(s), resulted in variations in the IC50 values, obtained in HeLa cells. 
Further investigations of the mechanism of action and of the structure-activity relationship of this 
class of ruthenium complexes, are of crucial importance for optimization of their activity. 
 
Table 15. Cytotoxicity of the tested agents in terms of IC50 values (M), obtained for 72 h of continuous drug 
action, by MTT assay. IC50 values present average (± SD). 
 IC50 ± SD (M)
*
  
Compound HeLa A549 LS-174 MRC-5 K562 
1 > 200 > 200 > 200 > 200 / 
2 132.26 ± 4.99 > 200 180.90 ± 10.12 > 200 / 
3 184.02 ± 16.16 > 200 > 200 > 200 / 
4 147.70 ± 7.99 > 200 > 200 > 200 / 
5 ND > 300 ND > 300 177.63±2.8 
 
> 200 denotes that IC50 was not obtained in the range of concentrations tested up to 200 M.  
**
 > 300 denotes that IC50 was not obtained in the range of concentrations tested up to 300 M. 
ND Not Determined 
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4.5. Effects of NAC or L-BSO on the cell survival of HeLa cells treated with 
complex 2  
 
 Taking into account redox-reactivity of Ru compounds bearing bipyridine moieties 
[3,14], we investigated whether cytotoxic potential of complex 2, in HeLa cells, could be altered 
in combination with pharmacological modulators of cell redox-homeostasis, such as L-
buthionine-sulfoximine (L-BSO) or N-acetyl-L-cysteine (NAC) [15-18]. Glutathione, present in 
millimolar intracellular concentrations, is a major determinant of the cellular redox status. L-
BSO acts as a specific inhibitor of γ-glutamylcysteine synthesis (γ-GCS), the rate-limiting 
enzyme for biosynthesis of glutathione (GSH). N-acetyl-L-cysteine (NAC), acts as GSH 
precursor and is effective in protecting cells from reactive oxygen species (ROS) mediated 
cytoxicity [19]. 
A preliminary dose-response study of L-BSO or NAC, for 72 h action in HeLa cells, was 
performed. Results showed more than 22% decrease of cell survival, in the concentration range 
above 2.5 µM of L-BSO, or above 30 µM of NAC (results not presented). Therefore the sub-
toxic concentrations of L-BSO (1 μM) or NAC (20 μM), were selected for further combinational 
drug study [20,21]. However pretreatment of HeLa cells (3 h) with BSO or NAC, did not 
significantly alter cell response to the action of complex 2 (Figure 18). Results suggested that 
ROS and GSH might not be tightly related to the mechanism of antiproliferative action of 
complex 2 in HeLa cells. 
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Figure 18. Effects of NAC and L-BSO on the cell survival in complex 2 treated HeLa cells. Exponentially growing 
cells were pre-treated with 20 μM NAC or 1 μM L-BSO and then after washing out, further treated with 50, 100 or 
200 μM with the complex 2 for 72 h. Bars represent average of triplicates ± SD. 
 
Effects of NAC or L-BSO on complex 2 induced cell cycle perturbations in HeLa cells. We 
performed further combinational drug study, to investigate whether pretreatment of HeLa cells 
by NAC (20 μM) or L-BSO (1 μM) may affect cell cycle perturbations, caused by complex 2. 
Sub-toxic concentrations of NAC or L-BSO, didn’t affect the cell cycle profile in HeLa cells, 
compared to the non-treated cells (Figure 19). Complex 2 at IC50 concentration (132 μM), 
induced slight cell cycle perturbations, characterized by the increase of sub-G1 content (7.57% 
compared to control 1.23%), decrease of cell number in G1 phase (52.17%, compared to control 
64.66%), and arrest in the S phase (21.40% relative to control 10.99%). Slower progression of 
cells through S phase of the cell cycle, clearly indicated potential of complex 2 to inhibit 
replication in HeLa cells, through DNA-interactions or by indirect manner (ROS production). 
Pre-treatment of HeLa cells with NAC (3 h) caused almost no alterations of cell cycle 
progression, comparing to the action of complex 2, as a single agent (Figure 19). On the other 
hand, pretreatment with L-BSO caused more pronounced changes in Sub-G1 phase (increase to 
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24.21%), as well as in G1 phase (decrease of cell number to 42.23%) (Figure 19). It seems that 
L-BSO, at sub-toxic concentrations potentiated apoptotic stimuli caused by complex 2. This 
result suggested that intracellular glutathione may affect action of complex 2 or may at least 
influence its intracellular availability for interaction with potential cellular targets. 
 
 
Figure 19. Effects of NAC and L-BSO on the cell cycle of complex 2-treated HeLa cells. Exponentially growing 
cells were pre-treated with 20 μM NAC or 1 μM L-BSO and then after washing out, further treated with complex 2 
(IC50 132 μM) for 72 h. Bars represent average of duplicates. 
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4.6. Interaction of complex 2 with DNA 
 
4.6.1. UV-vis spectroscopy 
 
Potential interaction of the complex 2 with DNA was studied in PBS at room temperature and 
the corresponding absorption spectrum in the absence and presence of DNA is shown in Figure 
20. A band at 355 nm can be assigned to intraligand π - π* transitions while a broad band located 
in the visible region at 462 nm is attributed to the metal-to-ligand charge transfer (MLCT) 
transitions [22]. As the concentration of DNA increased, both absorption bands displayed clear 
hypochromism but no obvious red shift. This observation is in agreement with recently published 
reports [23,24]. These studies suggested an intercalation mode of complex-DNA interaction, 
which usually results in hypochromism and bathochromism as a direct consequence of 
interaction between the aromatic chromophore and the base pairs of DNA. 
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Figure 20. Absorption spectra of complex 2 in DMSO (0.1 mM PBS) at pH = 7 upon the addition of DNA, [Ru] = 
20 ppm, [DNA] = 0-250 ppm. Arrow shows the absorbance changing upon increasing DNA. 
 
4.6.2. Cyclic voltammetry 
 
 Electrochemical measurements were performed for complex 2 as a useful complement 
method for UV-vis spectroscopic investigation of complex-DNA interaction. Cyclic 
voltammograms were recorded in the presence of increasing amounts of complex 2 (Figure 21). 
After addition of DNA, two reversible one-electron redox processes are detected. Shifts of E1/2 
toward more positive values in a positive potential range (0.20 < E1/2 < 0.90 V) indicate ability of 
this Ru(II) complex to interact with DNA as a result of intercalation mode [25]. 
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Figure 21. The cyclic voltammograms recorded in DMSO (0.1 mM PBS) at a boron-doped electrode upon the 
addition of the complex 2 ([DNA] = 20 ppm and [2] = 0-250 ppm) in a potential range a) 0.00 < E1/2 < 1.60 V and b) 
0.00 < E1/2 < 0.90 V. Arrow shows E1/2 shifts changing upon increasing complex's concentration. 
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5. CONCLUSION 
 
 
 
 
 In this thesis synthesis and structural characterization of new ruthenium(II) bipyridyl 
complexes of general formula, [RuL(bpy)2]PF6, (HL = 3-methylpyridine-2-carboxylic acid, 6-
methylpyridine-2-carboxylic acid, 5-bromopyridine-2-carboxylic acid and 6-bromopyridine-2-
carboxylic acid) were described. All compounds were characterized by various methods (NMR 
and IC spectroscopy, mass spectrometry and elemental analysis), including X-ray 
crystallography for complexes 3, 4 and 5. The octahedral Ru(II) complex cation consists of two 
bidentate bypiridyl ligands and and one ON bidentate picolinato ligand, counterbalanced by one 
PF6¯ anion. Electrochemical properties of the synthesized complex were investigated and the 
obtained results indicate that its electrochemical behavior is in accordance with literature data for 
Ru(II) complexes.  
Complexes showed moderate cytotoxicity, which may be due to the unfavorable ligand 
dissociation kinetics and off-target reactivity, when once in solution. 
Still, minor variations in the structure of the co-ligand resulted in variations in the resulting IC50 
values obtained in HeLa cells. Complex 2 exhibited the highest activity in cervical cancer HeLa 
cells, with IC50 value being 132.26 ± 4.99 (µM). Combinational drug studies revealed that L-
BSO did not affect cytotoxicity of the complex 2, though it modulated its effect on the cell cycle, 
by enhancing arrest in the S phase, and increasing Sub-G1 peak (fragmented DNA). Among 
ruthenium compounds bearing polypyridine moieties, several of them have proven to be 
mitochondria-targeting anticancer drug candidates, which often induce redox reactions inside 
cancer cells, resulting in an increase of reactive oxygen species (ROS). However, combinational 
drug studies using the ROS scavenger, NAC, did not affect the activity of the complex 2. For 
investigation of the binding mode of the complex 2 to DNA, UV-vis and cyclic voltammetry 
were employed. Both techniques suggest an intercalative mode of binding signifying that the 
complex 2 probably acts as DNA intercalator.  
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6. SUPPLEMENTARY MATERIAL  
 
 
SYNTHESIS, CHARACTERIZATION AND CYTOTOXICITY BIS(BIPYRIDINE) 
RUTHENIUM(II) COMPLEXES WITH PICOLINIC ACID DERIVATIVES 
 
Afia Baroud 
(Spectroscopic characterization of synthesized complexes) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
63 
 
Table of content: 
Fig. S1. 
1
H NMR spectrum of complex 1. 
Fig. S2. 
13
C NMR spectrum of complex 1. 
Fig. S3. IR spectrum of complex 1. 
Fig. S4. MS spectrum of complex 1. 
Fig. S5. 
1
H NMR spectrum of complex 2. 
Fig. S6. 
13
C NMR spectrum of complex 2. 
Fig. S7. IR spectrum of complex 2. 
Fig. S8. MS spectrum of complex 2. 
Fig. S9. 
1
H NMR spectrum of complex 3. 
Fig. S10. 
13
C NMR spectrum of complex 3. 
Fig. S11. IR NMR spectrum of complex 3. 
Fig. S12. MS spectrum of complex 3. 
Fig. S13. 
1
H NMR spectrum of complex 4. 
Fig. S14. 
13
C NMR spectrum of complex 4. 
Fig. S15. IR spectrum of complex 4. 
64 
 
Fig. S16. MS spectrum of complex 4. 
Fig. S17. 
1
H NMR spectrum of complex 5. 
Fig. S18. IR spectrum of complex 5. 
Fig. S19. MS spectrum of complex 5. 
 
65 
 
 
Fig. S1. 
1
H NMR spectrum of 1. 
66 
 
 
Fig. S2. 
13
C NMR spectrum of 1. 
 
67 
 
 
Fig. S3. IR spectrum of 1. 
 
68 
 
 
Fig. S4. MS spectrum of 1. 
 
69 
 
 
Fig. S5. 
1
H NMR spectrum of 2. 
 
70 
 
 
Fig. S6. 
13
C NMR spectrum of 2. 
 
71 
 
 
Fig. S7. IR spectrum of 2. 
 
 
 
72 
 
 
 
Fig. S8. MS spectrum of 2. 
 
73 
 
 
 
Fig. S9. 
1
H NMR spectrum of 3. 
 
74 
 
 
Fig. S10. 
13
C NMR spectrum of 3. 
 
75 
 
 
Fig. S11. IR spectrum of 3. 
 
 
 
76 
 
 
 
Fig. S12. MS spectrum of 3. 
 
 
77 
 
 
Fig. S13. 
1
H NMR spectrum of 4. 
 
78 
 
 
Fig. S14. 
13
C NMR spectrum of 4. 
 
79 
 
 
Fig. S15. IR spectrum of 4. 
 
 
 
80 
 
 
 
 
Fig. S16. MS spectrum of 4. 
 
81 
 
 
Fig. S17. 
1
H NMR spectrum of 5. 
 
 
 
 
 
82 
 
 
Fig. S18. IR spectrum of 5. 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
83 
 
 
 
Fig. S19. Mass spectrum of 5. 
 
 
84 
 
7. Curriculum Vitae 
 
 
Afya A. Baroud, Msc in Chemistry 
 
Date of birth: 08.03.1985 
 
Place of birth: Bani Waleed, Libya 
 
 
Education 
 
 
2013-   PhD student at Faculty of Chemistry, University of Belgrade 
 
Decembar 2012 Master of Science degree in Chemistry, Faculty of Chemistry, University 
of Belgrade 
 
2010-2012.  MSc studies, Faculty of Chemistry, University of Belgrade 
 
2003-2007. Bachelor of Science degree in Chemistry, Faculty of Science, University 
7
th
 of October, Bani Waleed, Libya 
 
2000-2003. General Certificate of  Secondary Education in Science-Albark Akatif  
School, Bani Waleed, Libya 
 
1992-2000. Preparatory School Certificate, Alfajer Algadeid School, Bani Waleed, 
Libya 
 
Publications 
 
1. A. A. Baroud, Lj. E. Mihajlović-Lalić, D. Stanković, Marijana Kajzerberger, K. V. 
Hecke, S. Grgurić-Šipka, A. Savić: New ruthenium(II) bipyridyl complex: synthesis, 
crystal structure and cytotoxicity, J. Serb. Chem. Soc., (2017) DOI: 
10.2298/JSC170109025B. 
2. A. A. Baroud, Lj. E. Mihajlović-Lalić, N. Gligorijević, S. Aranđelović, D. Stanković, S. 
Radulović, K. V. Hecke, A. Savić, S. Grgurić-Šipka: Ruthenium(II) bipyridyl complexes: 
85 
 
from synthesis and crystal structures to electrochemical and cytotoxicity investigation, J. 
Coord. Chem., 70 (2017) 831-847. 
3. A. Savić, A. A. Baroud, Sanja Grgurić-Šipka: The new ruthenium(II)-bipyridyl complex 
with O,O'-diethyl-(S,S)-ethylenediamine-N,N'-di-2-(3-cyclohexyl)propanoate: synthesis 
and characterization. Maced. J. Chem. Chem. Eng., 2014, 33, 59-64. 
 
 
Conferences  
 
1. A. A. Baroud, A. R. Savić, Ruthenium(II)-bipyridyl complex as PDT agent, Prva 
konferencija Kluba mladih hemičara, Beograd, 2012. Izvodi radova HS P15, str. 62.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
86 
 
Прилог 1. 
Изјава о ауторству 
 
 
 
Потписанa: Afya A. Baroud 
 
број уписа ДХ54/2012 
 
Изјављујем 
да је докторска дисертација под насловом  
Синтеза, карактеризација и цитотоксичност бис(бипиридин) рутенијум(II) комплекса 
са дериватима пиколинске киселине 
 
 резултат сопственог истраживачког рада, 
 да предложена дисертација у целини ни у деловима није била предложена за 
добијање било које дипломе према студијским програмима других високошколских 
установа, 
 да су резултати коректно наведени и  
 да нисам кршио/ла ауторска права и користио интелектуалну својину других лица.  
 
  Потпис докторанда 
У Београду, 9.3.2017. 
_________________________ 
 
 
 
 
 
 
 
87 
 
Прилог 2. 
 
Изјава o истоветности штампане и електронске верзије 
докторског рада 
 
 
Име и презиме аутора: Afya A. Baroud 
Број уписа: ДХ54/2012 
Студијски програм: доктор хемијских наука 
Наслов рада: Синтеза, карактеризација и цитотоксичност бис(бипиридин) рутенијум(II) 
комплекса са дериватима пиколинске киселине 
Ментор: др Сања Гргурић-Шипка, редовни професор Хемијског факултета, Универзитета 
у Београду 
 
Потписани Afya A. Baroud 
 
изјављујем да је штампана верзија мог докторског рада истоветна електронској верзији 
коју сам предао/ла за објављивање на порталу Дигиталног репозиторијума 
Универзитета у Београду.  
Дозвољавам да се објаве моји лични подаци везани за добијање академског звања 
доктора наука, као што су име и презиме, година и место рођења и датум одбране рада.  
Ови лични подаци могу се објавити на мрежним страницама дигиталне библиотеке, у 
електронском каталогу и у публикацијама Универзитета у Београду. 
 
            Потпис докторанда  
У Београду, 9.3.2017. 
   _________________________ 
 
 
88 
 
Прилог 3. 
Изјава о коришћењу 
 
Овлашћујем Универзитетску библиотеку „Светозар Марковић“ да у Дигитални 
репозиторијум Универзитета у Београду унесе моју докторску дисертацију под насловом: 
Синтеза, карактеризација и цитотоксичност бис(бипиридин) рутенијум(II) комплекса са 
дериватима пиколинске киселине 
која је моје ауторско дело. 
Дисертацију са свим прилозима предао/ла сам у електронском формату погодном за 
трајно архивирање.  
Моју докторску дисертацију похрањену у Дигитални репозиторијум Универзитета у 
Београду могу да користе  сви који поштују одредбе садржане у одабраном типу лиценце 
Креативне заједнице (Creative Commons) за коју сам се одлучио/ла. 
1. Ауторство 
2. Ауторство - некомерцијално 
3. Ауторство – некомерцијално – без прераде 
4. Ауторство – некомерцијално – делити под истим условима 
5. Ауторство –  без прераде 
6. Ауторство –  делити под истим условима 
(Молимо да заокружите само једну од шест понуђених лиценци, кратак опис лиценци дат 
је на полеђини листа). 
 
  Потпис докторанда 
У Београду, 9.3.2017. 
  ____________________ 
 
 
 
89 
 
1. Ауторство - Дозвољавате умножавање, дистрибуцију и јавно саопштавање дела, и 
прераде, ако се наведе име аутора на начин одређен од стране аутора или даваоца 
лиценце, чак и у комерцијалне сврхе. Ово је најслободнија од свих лиценци. 
2. Ауторство – некомерцијално. Дозвољавате умножавање, дистрибуцију и јавно 
саопштавање дела, и прераде, ако се наведе име аутора на начин одређен од стране 
аутора или даваоца лиценце. Ова лиценца не дозвољава комерцијалну употребу дела. 
3. Ауторство - некомерцијално – без прераде. Дозвољавате умножавање, дистрибуцију и 
јавно саопштавање дела, без промена, преобликовања или употребе дела у свом делу, 
ако се наведе име аутора на начин одређен од стране аутора или даваоца лиценце. Ова 
лиценца не дозвољава комерцијалну употребу дела. У односу на све остале лиценце, 
овом лиценцом се ограничава највећи обим права коришћења дела.  
 4. Ауторство - некомерцијално – делити под истим условима. Дозвољавате умножавање, 
дистрибуцију и јавно саопштавање дела, и прераде, ако се наведе име аутора на начин 
одређен од стране аутора или даваоца лиценце и ако се прерада дистрибуира под истом 
или сличном лиценцом. Ова лиценца не дозвољава комерцијалну употребу дела и 
прерада. 
5. Ауторство – без прераде. Дозвољавате умножавање, дистрибуцију и јавно 
саопштавање дела, без промена, преобликовања или употребе дела у свом делу, ако се 
наведе име аутора на начин одређен од стране аутора или даваоца лиценце. Ова 
лиценца дозвољава комерцијалну употребу дела. 
6. Ауторство - делити под истим условима. Дозвољавате умножавање, дистрибуцију и 
јавно саопштавање дела, и прераде, ако се наведе име аутора на начин одређен од 
стране аутора или даваоца лиценце и ако се прерада дистрибуира под истом или 
сличном лиценцом. Ова лиценца дозвољава комерцијалну употребу дела и прерада. 
Слична је софтверским лиценцама, односно лиценцама отвореног кода. 
 
 
